Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status

BACKGROUND: Patients with treatment-naive advanced urothelial cancer (UC) Ineligible for cisplatin-based chemotherapy are typically older and have comorbidities, representing a difficult-to-treat population. OBJECTIVE: To evaluate the safety and antitumor activity of first-line pembrolizumab in subg...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Urol Oncol
Main Authors: Grivas, Petros, Plimack, Elizabeth R., Balar, Arjun V., Castellano, Daniel, O’Donnell, Peter H., Bellmunt, Joaquim, Powles, Thomas, Hahn, Noah M., de Wit, Ronald, Bajorin, Dean F., Ellison, Misoo C., Frenkl, Tara L., Godwin, James L., Vuky, Jacqueline
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8246631/
https://ncbi.nlm.nih.gov/pubmed/32423837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.euo.2020.02.009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados